Drugs / MR001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06134531 | Nov 2023 → Jul 2026 overdue | cancer | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07208149 | Jan 2026 → Sep 2028 expected | triple-negative breast carcinoma | Shenzhen Majory Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07235202 | Dec 2025 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Shenzhen Majory Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07235202 ↗ |
| Action | Inhibit | “blocking TGF-β signalling in CD4+ T cells” PMID 33087933 ↗ Oct 2020 |
| Route | Intravenous | “Intravenously (IV)” NCT06134531 ↗ |
| Target | CD4 | “anti-CD4/anti-TGFβ1 bispecific antibody” NCT06134531 ↗ |